TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · major macro event coming up
SPRY

ARS Pharmaceuticals, Inc

Healthcare · Biotechnology · —

2.80$ +5.3% vs. previous close Closing price · As of: Nov 6, 2026

Ownership

Ownership Structure

Who owns ARS Pharmaceuticals, Inc (SPRY)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 48.3% of the shares are freely tradable; institutional investors hold 95.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 95.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 16.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 48.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 28.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 99Mio.

Largest Shareholders

Institutions

Institutions SPRY
Name Stake (%) Shares Change (%) Date
RA Capital Management, LLC 10.92 10,860,977 +0.0 06/30/2026
Rubric Capital Management LP 8.59 8,540,861 +6.8 06/30/2026
Orbimed Advisors LLC 8.33 8,288,510 +0.0 06/30/2026
Deerfield Management Co 7.55 7,503,812 +0.0 06/30/2026
BlackRock Inc 5.34 5,311,319 +6.0 06/30/2026
Tyro Capital Management LLC 4.48 4,459,337 +50.2 06/30/2026
Aberdeen Group PLC 4.19 4,170,629 +1.4 06/30/2026
SR ONE CAPITAL MANAGEMENT, LP 4.04 4,012,903 +0.0 06/30/2026
State Street Corp 3.75 3,730,623 +2.4 06/30/2026
Capital World Investors 2.77 2,754,931 +0.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?